Sign Up to like & get
recommendations!
0
Published in 2019 at "Turkish Journal of Pharmaceutical Sciences"
DOI: 10.4274/tjps.galenos.2018.46547
Abstract: Objectives: The fixed dose combination of saxagliptin and dapagliflozin is a recently approved antidiabetic medication. It is marketed under the brand name Qtern. The aim of this study was to develop a simple, rapid, sensitive,…
read more here.
Keywords:
human plasma;
saxagliptin dapagliflozin;
method;
dapagliflozin human ... See more keywords